Targeting Mesothelin With CAR T Cells Shows Promise in Treating CCA Mesothelin seems to be a promising target for chimeric antigen receptor (CAR) T cell therapy against cholangiocarcinoma (CCA).

#Mesothelin, a tumor differentiation antigen that is highly expressed in #Cholangiocarcinoma (#CCA), is a promising target for chimeric antigen receptor (CAR) T cell therapy against the disease. Study in Hepatology Communications.

Read more: https://bit.ly/4t0NK49

Decoding the role of mesothelin in tumor dynamics and targeted treatment innovations - Molecular Biomedicine Mesothelin (MSLN) is among the most studied cancer-related antigens, and it is extensively studied as a therapeutic target for the treatment of various malignancies, including pleural mesothelioma, pa...

#Review
Decoding the role of mesothelin in tumor dynamics and targeted treatment innovations doi.org/10.1186/s435...

#Mesothelin #TargetedTherapy #TumorMicroenvironment #TME #CAR_TCells #BispecificAntibodies

CD3ε-derived #ChimericAntigenReceptors targeting #HER2 or #mesothelin exhibit potent and enhanced #tumoricidal activity, with a lower tonic signaling, reduced exhaustion, and improved differentiation into memory populations. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...

This recent article found that #mesothelin is a viable CAR T-cell target for #meningiomas, and mesothelin-specific CAR T-cell therapy shows strong preclinical efficacy.

Read more in #NeuroOncology:

bit.ly/43bm94Q